Peginterferon beta-1a (Plegridy) for multiple sclerosis.

  • Published 2015 in The Medical letter on drugs and therapeutics

Abstract

Pegylated interferon beta-1a (Plegridy) injected subcutaneously every 2 weeks appears to be similar in its efficacy and adverse effects to older interferon formulations that must be injected more frequently. 

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics